TherapeuticsMD, Inc. (TXMD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TXMD currently has 11.6M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 0.6% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 11.6M shares outstanding |
12M | 0 |
| Mar 30, 2026 |
10-K filing | 11.6M shares outstanding |
12M | 0 |
| Nov 12, 2025 |
10-Q filing | 11.6M shares outstanding |
12M | 0 |
| Aug 12, 2025 |
10-Q filing | 11.6M shares outstanding |
12M | 0 |
| May 13, 2025 |
10-Q filing | 11.6M shares outstanding |
12M | 0 |
| Mar 27, 2025 |
10-K filing | 11.6M shares outstanding |
12M | 0 |
| Nov 12, 2024 |
10-Q filing | 11.5M shares outstanding |
12M | 0 |
| Aug 12, 2024 |
10-Q filing | 11.5M shares outstanding |
12M | 0 |
| May 10, 2024 |
10-Q filing | 11.5M shares outstanding |
12M | 0 |
| Mar 29, 2024 |
10-K filing | 10.4M shares outstanding |
10M | 0 |
| Nov 14, 2023 |
10-Q filing | 10.7M shares outstanding |
11M | 0 |
| Aug 14, 2023 |
10-Q filing | 10.2M shares outstanding |
10M | 0 |
| May 15, 2023 |
10-Q filing | 9.8M shares outstanding |
9.8M | 0 |
| Apr 07, 2023 |
10-K filing | 9.4M shares outstanding |
9.4M | 0 |
| Nov 14, 2022 |
10-Q filing | 9.3M shares outstanding |
9.3M | 0 |
| Aug 15, 2022 |
10-Q filing | 9.1M shares outstanding |
9.1M | 0 |
| May 16, 2022 |
10-Q filing | 8.6M shares outstanding |
8.6M | 0 |
| May 06, 2022 |
Stock Split
8-K filing: Stock split 1-for-50 | Outstanding: 397,992,000 → 7,959,840 |
8M | 0 |
| Mar 24, 2022 |
POS AM filing: The filing is a POS AM (Post-Effective Amendment) which registers the offer and sale of up to $209,377,660 in the aggregate of common stock, preferred stock, debt securities, depositary shares, and purchase contracts, and also covers an at-the-market offering of common stock up to $59,377,660 through Cantor Fitzgerald. |
400M | 0 |
| Mar 23, 2022 |
10-K filing | 398.0M shares outstanding |
400M | 0 |
| Nov 12, 2021 |
10-Q filing | 422.2M shares outstanding |
420M | 0 |
| Aug 04, 2021 |
10-Q filing | 394.1M shares outstanding |
390M | 0 |
| May 06, 2021 |
10-Q filing | 393.2M shares outstanding |
390M | 0 |
| Mar 04, 2021 |
10-K filing | 387.8M shares outstanding |
390M | 0 |
| Feb 16, 2021 |
8-K filing: TherapeuticsMD, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 59,459,460 shares of common stock at $0.001 par value, with an underwriter option to purchase up to 8,918,919 additional shares, expected to close on February 16, 2021, with net proceeds of approximately $97.1 million. ($97.1M proceeds) |
270M | 0 |
| Nov 09, 2020 |
10-Q filing | 272.8M shares outstanding |
270M | 0 |
| Aug 07, 2020 |
10-Q filing | 272.3M shares outstanding |
270M | 0 |
| May 06, 2020 |
10-Q filing | 271.7M shares outstanding |
270M | 0 |
| Feb 24, 2020 |
POS AM filing: The filing is a post-effective amendment to a registration statement for the potential offering of common stock, preferred stock, debt securities, depository shares, warrants, purchase contracts and units. |
N/A | 0 |
| Feb 24, 2020 |
10-K filing | 271.5M shares outstanding |
270M | 0 |